122 related articles for article (PubMed ID: 36448065)
21. Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study.
Abdel-Rahman O; Fazio N
J Neuroendocrinol; 2021 May; 33(5):e12971. PubMed ID: 33870570
[TBL] [Abstract][Full Text] [Related]
22. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
[TBL] [Abstract][Full Text] [Related]
23. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
25. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
26. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients.
Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ
World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
29. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.
Goretzki PE; Mogl MT; Akca A; Pratschke J
Rev Endocr Metab Disord; 2018 Jun; 19(2):169-178. PubMed ID: 30280290
[TBL] [Abstract][Full Text] [Related]
30. Low Prognostic Nutritional Index Is Common and Associated with Poor Outcomes following Curative-Intent Resection for Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Xiang JX; Qian YR; He J; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Lv Y; Zhang XF; Pawlik TM
Neuroendocrinology; 2024; 114(2):158-169. PubMed ID: 37703840
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
32. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
[No Abstract] [Full Text] [Related]
33. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
34. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms.
Sekerci A; Turk HM; Demir T; Seker M; Akcakaya A; Arici DS
J Coll Physicians Surg Pak; 2020 Aug; 30(8):863-867. PubMed ID: 32893801
[TBL] [Abstract][Full Text] [Related]
36. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
37. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
38. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.
Shiba S; Morizane C; Hiraoka N; Sasaki M; Koga F; Sakamoto Y; Kondo S; Ueno H; Ikeda M; Yamada T; Shimada K; Kosuge T; Okusaka T
Pancreatology; 2016; 16(1):99-105. PubMed ID: 26718527
[TBL] [Abstract][Full Text] [Related]
40. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
